Teacher Retirement System of Texas Sells 12,781 Shares of Omnicell, Inc. (NASDAQ:OMCL)

Teacher Retirement System of Texas decreased its holdings in shares of Omnicell, Inc. (NASDAQ:OMCL) by 47.9% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 13,901 shares of the company’s stock after selling 12,781 shares during the quarter. Teacher Retirement System of Texas’ holdings in Omnicell were worth $486,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Jane Street Group LLC grew its position in shares of Omnicell by 7.4% during the 4th quarter. Jane Street Group LLC now owns 54,282 shares of the company’s stock worth $2,417,000 after buying an additional 3,725 shares during the period. Invesco Ltd. raised its position in shares of Omnicell by 2.4% in the 4th quarter. Invesco Ltd. now owns 219,453 shares of the company’s stock valued at $9,770,000 after acquiring an additional 5,063 shares during the period. Mariner LLC boosted its stake in Omnicell by 16.1% during the 4th quarter. Mariner LLC now owns 9,075 shares of the company’s stock worth $404,000 after acquiring an additional 1,261 shares during the last quarter. Vanguard Group Inc. grew its holdings in Omnicell by 0.5% during the fourth quarter. Vanguard Group Inc. now owns 5,562,165 shares of the company’s stock valued at $247,628,000 after purchasing an additional 28,573 shares during the period. Finally, Walleye Trading LLC acquired a new position in Omnicell during the fourth quarter valued at approximately $314,000. 97.70% of the stock is owned by institutional investors.

Analyst Ratings Changes

OMCL has been the topic of a number of recent analyst reports. Wall Street Zen raised shares of Omnicell from a “buy” rating to a “strong-buy” rating in a research report on Saturday, July 12th. Piper Sandler reaffirmed an “overweight” rating on shares of Omnicell in a research note on Friday, May 23rd. JPMorgan Chase & Co. reduced their target price on Omnicell from $44.00 to $36.00 and set a “neutral” rating on the stock in a report on Thursday, March 20th. Benchmark lowered their price target on Omnicell from $62.00 to $40.00 and set a “buy” rating for the company in a report on Wednesday, May 7th. Finally, Bank of America raised their price target on Omnicell from $30.00 to $34.00 and gave the stock a “neutral” rating in a research report on Friday, May 23rd. Three investment analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Omnicell currently has an average rating of “Moderate Buy” and an average price target of $44.83.

Omnicell Price Performance

OMCL stock opened at $27.78 on Thursday. The stock has a 50-day moving average price of $29.02 and a two-hundred day moving average price of $34.41. Omnicell, Inc. has a 1 year low of $22.66 and a 1 year high of $55.75. The stock has a market cap of $1.30 billion, a PE ratio of 60.39, a price-to-earnings-growth ratio of 8.17 and a beta of 0.76. The company has a current ratio of 1.38, a quick ratio of 1.23 and a debt-to-equity ratio of 0.13.

Omnicell (NASDAQ:OMCL) last posted its quarterly earnings data on Tuesday, May 6th. The company reported $0.26 earnings per share for the quarter, topping the consensus estimate of $0.16 by $0.10. Omnicell had a return on equity of 4.60% and a net margin of 1.87%. The company had revenue of $269.67 million during the quarter, compared to analysts’ expectations of $260.18 million. During the same period in the prior year, the firm earned $0.03 earnings per share. Omnicell’s revenue for the quarter was up 9.5% compared to the same quarter last year. Equities analysts forecast that Omnicell, Inc. will post 1.09 EPS for the current fiscal year.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.